42 results about "Immune clearance" patented technology

The invention discloses a logistic distribution partitioning balance optimizing method, which builds a logistic distribution partitioning multipurpose optimal model and designs immune algorithm solving. A model minimizes zone line number as well as the total distance and the total working time of all lines to balance the line number, the total distance, the total working time and the total demanded quantity of different zones. The model adopts VRP, TSP and a shortest path algorithm to ensure the optimization of a distribution path while balancing zones. An arithmetic operator and a mechanism aroused by designed immunity comprise clonal selection, high-frequency variation, immune clearance and immunological memory, and two stages are searched to solve by the synergy of the construction and the zone of the initial partitioning scheme. The method of the invention is suitable for the partitioning balance optimization of large-scale logistic distribution, and can lower logistic distribution cost, improve logistic distribution efficiency and improve the degree of satisfaction of customers to staff.

The invention discloses antibody nanoparticles coated by natural red cell membranes for antibody drug delivery and a preparation method of the antibody nanoparticles. The red cell membranes in the invention are extracted from experimental rats, most of the contents and unrelated proteins are removed after the red cell membranes are treated, and protein nanoparticles formed by antibodies are coated with the obtained red cell membranes. The method is suitable for coating nanoparticles formed by different antibodies through the red cell membranes, can improve the stabilities and the in-vivo circulation times of free antibodies, and further reduces the body immunity clearance rate.

The invention relates to a bionic magnetosome loaded with siRNA and a preparation method of the magnetosome, and belongs to the field of chemistry and biomedicine. According to the bionic magnetosome, water-soluble MNC serves as the kernel and is wrapped by a white cell membrane, and siRNA is loaded between the MNC and the white cell membrane; antibodies or peptides with modifying groups can be coupled outside the white cell membrane of the bionic magnetosome in a covalence mode. By preparing MNC, M and MNC:siRNA and mixing an MNC:siRNA solution, an M solution and a buffer solution, the bionic magnetosome is obtained; the white cell membrane of the bionic magnetosome is modified by the peptides or antibodies through the modifying groups, and the bionic magnetosome coupled with the antibodies or peptides is obtained. The MNC in the bionic magnetosome has positive charges, can adsorb siRNA and is wrapped by M for bionics, a focus is reached efficiently and rapidly, and meanwhile immune elimination of organisms is avoided.

The invention discloses a feed additive for reducing cow body cells and treating recessive mastitis and a preparation method of the feed additive. The feed additive is prepared from the following raw materials in parts by weight: 10-15 parts of antibacterial peptide, 5-10 parts of geobacillus sp, 10-15 parts of yeast, 15-20 parts of cottonrose hibiscus leaf, 20-30 parts of andrographis paniculata, 10-20 parts of thesium chinense, 5-10 parts of cowherb seed, 15-20 parts of mongolian dandelion herb, 10-20 parts of epimedium, 20-30 parts of astragalus membranaceus, 5-10 parts of lindera aggregata leaf, 1-5 parts of sea buckthorn seed powder, 1-5 parts of corn pollen, 0.2-0.3 part of organic chelated zinc, 0.3-1 part of organic chromium and 8-15 parts of coated threonine. The additive can quickly reduce the body cell number, quickly cure the recessive mastitis, enable a cow to quickly restore to be the healthy production state, avoid generation of clinical mastitis, comprehensively improve the immunologic function of the body of the cow in the lactation period, effectively prevent generation of various diseases, highly improve the anti-stress capability of the cow in the perinatal period, effectively prevent generation of antenatal and puerperal diseases, highly improve the vaccine protection rate, strengthen the immune antibody level, and avoid immune clearance, immune inhibition and vaccine stress.

The present invention provides a tumor-targeted adenovirus polymer drug delivery system, which has the following characteristics that (1) a targeted molecule ACPPs and tumor MMPs overexpression generation enzyme are subjected to an enzyme-substrate reaction so as to provide the tumor targeting property; (2) the adenovirus delivery immune clearance effect is reduced, wherein the immune clearance of the reaction product ACPPs-pc-Ad.mda-7. egfp is less, such that the circulating half-life is long so as to reduce the adenovirus delivery amount and increase the adenovirus therapy effect; (3) the adenovirus is positioned in the cytoplasm so as to easily express the therapy gene, wherein the adenovirus is mediated to across the cell membrane barrier through the membrane penetrating mechanism of ACPPs and is positioned in the cell cytoplasm so as to solve the problems of difficult macromolecule drug transmembrane transportion and low therapy gene expression efficiency; and (4) the anti-tumor spectrum is wide. According to the present invention, the drug delivery system is the melanoma differentiation associated gene, such that the growth inhibition and the apoptosis of a variety of cancer cells can be promoted, and significant advantages are provided for anti-tumor, tumor inhibition, toxic-side effect reducing and other fields.

Disclosed herein are methods of promoting the aggregation and/or immune clearance of oral bacteria using oral care compositions comprising metal-amino acid complexes.

The invention discloses a multifunctional liposome based on hydrogen peroxide response and a preparation method and application thereof, and belongs to the technical field of nano materials. The multifunctional liposome based on hydrogen peroxide response is jointly composed of phosphatidylserine and biblock polymer polyethylene glycol-polyacrylate propylene; and the preparation method includes the steps of preparation of PEG-PPS and preparation of the multifunctional liposome in response to hydrogen peroxide. The multifunctional liposome based on hydrogen peroxide response is used for coatinga dual-mode probe FITC-SiO2@Fe3O4 and can be used for in-vivo imaging; and the multifunctional liposome based on hydrogen peroxide response is used for coating anti-atherosclerosis drugs and can be used for drug release in vivo. According to the multifunctional liposome based on hydrogen peroxide response and the preparation method and application thereof, biodegradable polyethylene glycol is conjugated to the outer surface of the liposome to produce an invisible carrier, and immune clearance is prevented; and meanwhile, the traditional polyethylene glycol is specially modified, and while biocompatibility is retained and the hydrogen peroxide can be responded to release imaging agents or the drugs.

This invention pertains to pharmaceutical compositions comprising a glucocorticoid for use in the treatment of diseases by immunoablation. The compositions of the invention may be for use in the treatment of diseases that are mediated by immune cells such as lymphocytes.

The invention relates to a natural cell membrane derived novel ultrasonic contrast agent, in particular to a preparation method of the ultrasonic contrast agent and an application of the ultrasonic contrast agent to the respects of diagnosis and treatment of various diseases of cardiovascular diseases, cancer and the like. The ultrasonic contrast agent is characterized in that membrane components are completely from natural cell membranes, then gas or liquid is wrapped or loaded in the membrane components, and the novel contrast agent can approximately maintain structural integrity and function activity of the natural cell membranes. The novel contrast agent can maintain original function activity of the cell membranes, so that the novel contrast agent has the capacity of efficiently avoiding immune elimination in vivo, and blood long circulation capacity, and has favorable active target properties.

The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO−) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO− cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh−(“O−”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O− parent cell line. These new, novel HIPO− cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O− pluripotent stem cells (iPSCO−) and O− embryonic stem cells (ESCO−). The invention further provides universally acceptable “off”-the-shelf pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

The invention discloses a platelet-derived growth factor receptor alpha (PDGFRalpha) mutation related antigen short peptide and an application thereof. The sequence of the PDGFRalpha mutation relatedantigen short peptide is shown in any one of SEQ ID NO:1-20. The short peptide has high affinity with the MHC I molecule on dendritic cells (DCs), can effectively stimulate and induce production of specific cytotoxic T lymphocytes (CTLs), and can be used for immune clearance of PDGFRalpha gene mutant cells, thereby preventing the occurrence of PDGFRalpha gene mutation-related diseases, especiallypreventing PDGFRalpha gene mutation-related tumor diseases; therefore, the PDGFRalpha antigen short peptide provided by the invention has the potential of good polypeptide vaccine and DC vaccine, andhas good clinical transformation and disease prevention potential. Moreover, the PDGFRalpha antigen short peptide provided by the invention has a shorter length and low chemical synthesis difficulty,can be directly used to synthesize a high-purity product, and has greatly reduced application costs, a clear effect, and very good application prospects.

The invention discloses a bionic drug-loading nano-system combining cell membrane antagonism with nano-enzyme, a preparation method and application. The system comprises a shell of a cell membrane for loading chemotherapeutic drugs and an inner core of a nano-enzyme modified high-molecular polymer nano-microsphere for loading oxygen-carrying bodies. The bionic nano-carrier maintains the biological activity of cell membrane protein, improves the immune clearance avoiding capacity and biocompatibility of nano-particles, prolongs the blood circulation time of the nano-particles and improves the in-vivo biological distribution of the nano-particles. The drug-loading nano-microsphere is uniform in morphology, has long blood circulation time, can generate a cascade catalytic reaction to generate a large amount of active oxygen, kills leukemia cells, and can effectively inhibit recurrence and metastasis of leukemia; and a new strategy for cooperative treatment of leukemia is provided. The system combines nano-enzyme chemical power treatment with bionic treatment and drug chemotherapy of cell membranes, bone marrow targeted treatment of leukemia can be realized, and the problems of metastasis, recurrence, drug resistance and the like of leukemia are expected to be solved.

The invention discloses an antigen peptide related to colorectal cancer driver gene mutation. The antigen peptide related to colorectal cancer driver gene mutation is related to mutation of at least two genes in PIK3CA, APC, PCBP1, NRAS, SMAD2, FBXW7, CTNNB1 and KMT2D. The sequences of the antigen peptides related to colorectal cancer driver gene mutation are at least two of SEQ No.1-16; according to the application of the antigen peptide, the antigen peptide is used for inducing generation of specific cytotoxic T cell clone; and the antigen peptide has high affinity with MHC I molecules on DC cells, can effectively stimulate and induce generation of specific cytotoxic T lymphocytes, can be used for immune clearance of tumor cells with driving gene mutation related to colorectal cancer, and has good treatment potential.

The invention discloses an antigen peptide related to lung cancer driver gene mutation. Lung cancer driver genes are at least two of EGFR, FAT4, KMT2C, KEAP1, KRAS, RB1 and TP53. The sequences of the antigen peptides are at least two of SEQ No.1-47. According to the application of the antigen peptide, the antigen peptide is used for inducing generation of specific cytotoxic T cell clone. The antigen peptide has high affinity with MHC I molecules on DC cells, can effectively stimulate and induce generation of specific cytotoxic T lymphocytes, can be used for immune clearance of tumor cells with lung cancer related driver gene mutation, and has good treatment potential.

The invention discloses an antigen peptide related to esophagus cancer driver gene mutation. Esophagus cancer driver genes are at least two of EPCAM, MUC1, GPC3, LRP1B, ERBB4 and PREX2; the sequence of the antigen peptide includes at least two of SEQ No.1-12; according to the application of the antigen peptide, the antigen peptide is used for inducing generation of specific cytotoxic T cell clone; the antigen peptide has high affinity with MHC I molecules on DC cells, can effectively stimulate and induce generation of specific cytotoxic T lymphocytes, can be used for immune clearance of esophagus cancer related driver gene mutation tumor cells, and has good treatment potential.

The invention discloses an antigen peptide related to breast cancer driver gene mutation. A breast cancer driver gene is at least two of ABCB11, ESR1, GATA3, PALB2, SNX4, SLC24A4, HAUS3 and KMT2C; the sequences of the antigen peptides are at least two of SEQ No.1-18; and according to the application of the antigen peptide, the antigen peptide is used for inducing generation of specific cytotoxic T cell clone. The antigen peptide has high affinity with MHC I molecules on DC cells, can effectively stimulate and induce generation of specific cytotoxic T lymphocytes, can be used for immune clearance of breast cancer related driver gene mutation tumor cells, and has good treatment potential.

The invention discloses an antigen peptide related to colorectal cancer and application of the antigen peptide, the amino acid sequence of the antigen peptide is one of SEQ ID NO.1-SEQ ID NO.23, the antigen peptide is directly identified from colorectal cancer tumor tissues and can effectively stimulate autologous T lymphocytes of patients to generate immune response, some antigen peptides are shared among the patients with colorectal cancer, and the antigen peptide can be used for treating the colorectal cancer. The polypeptide can be used for preparing peptide vaccines or TCR-T lymphocytes and mediating immune clearance of related colorectal cancer tumor cells, and has good treatment potential.

The invention relates to the technical field of regulation of secretion of virus specific antibodies, and discloses 30 rats with the weight of 250-300g, half female rats and half male rats, the rats are randomly divided into three groups in a layered manner according to the weight, the three groups are subjected to experimental operation respectively, and sample collection and detection are performed after re-culture. According to an animal experiment operation method for improving antibody secretion of a novel coronavirus vaccine to special crowds, autologous lymphocytes are subjected to in-vitro induction and then are fed back; data can be obtained in an experiment to show that the antibody level of the autologous feedback of the in-vitro induced lymphocytes is in jumping increase; the experimental data can show that the operation method can overcome the defect that the elderly and the weak and sick people respond slowly or do not respond to vaccines; the specific virus immune clearance effect is improved; therefore, the occurrence rate of severe cases is reduced; and the method has a certain treatment effect on the severe cases.